AI assistant
MaaT Pharma — Share Issue/Capital Change 2025
Jul 7, 2025
1494_dva_2025-07-07_0cfcc331-3cb7-4f8a-adc8-4a574bbe047d.pdf
Share Issue/Capital Change
Open in viewerOpens in your device viewer
Ma P aT
Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital
Article 223-16 of the General Regulations of the Financial Markets Authority (AMF - Autorité des Marchés Financiers)
Lyon, France, July 7, 2025 – 6:00 pm CET – MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies™ (MET) dedicated to enhancing survival for patients with cancer through immune modulation, today published the number of shares comprising the share capital and the total number of voting rights (Article L. 233-8 of the French Commercial Code (Code de commerce) and Article 223-16 of the General Regulations of French Autorité des Marchés Financiers (AMF)) on June 30, 2025.
Listing place: Euronext Paris
ISIN code: FR0012634822
Website: www.maatpharma.com
| Date | Total number of shares comprising the share capital | Total number of theoretical voting rights (1) | Total number of effective voting rights (2) |
|---|---|---|---|
| 06/30/25 | 16,135,971 | 16,135,971 | 16,135,971 |
(1) In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended.
(2) Effective voting rights correspond to the total number of voting rights that may be used at a General Meeting. The total number of effective voting rights is calculated without taking into account the shares with suspended voting rights.
About MaaT Pharma
MaaT Pharma is a leading, late-stage clinical company focused on developing innovative gut microbiome-driven therapies to modulate the immune system and enhance cancer patient survival. Supported by a talented team committed to making a difference for patients worldwide, the Company was founded in 2014 and is based in Lyon, France. As a pioneer, MaaT Pharma is leading the way in bringing the first microbiome-driven immunomodulator in
MAAT
VICTOR
COUNCIL
oncology. Using its proprietary pooling and co-cultivation technologies, MaaT Pharma develops high diversity, standardized drug candidates, aiming at extending life of cancer patients. MaaT Pharma has been listed on Euronext Paris (ticker: MAAT) since 2021.
Contacts
MaaT Pharma – Investor Relations
Guilhaume DEBROAS, Ph.D.
Head of Investor Relations
+33 6 16 48 92 50
[email protected]
MaaT Pharma – Media Relations
Pauline RICHAUD
Senior PR & Corporate Communications
Manager
+33 6 14 06 45 92
[email protected]
2/2